NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT
Post# of 175
(Total Views: 231)
Posted On: 03/14/2023 4:00:52 PM
NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Acquires LIVEMOR Assets
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has acquired substantially all assets from LIVMOR, a digital health solutions company. Specifically, LIVMOR offers a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition allows HeartBeam to extend its reach with LIVEMOR’s FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and its physician-prescribed integrated patient-care platform. The acquisition gives HeartBeam full ownership of the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. HeartBeam and LIVMOR partnered earlier this year to build a HeartBeam-branded version of LIVMOR’s FDA-cleared, Halo, cloud-based software platform designed to connect physicians with patients. Included in the acquisition is three issued United States patents; LIVMOR technology, such as the Halo AF Detection System; LIVMOR’s business contracts and relationships; and all Samsung watch and tablet inventory; HeartBeam also hired LIVMOR’s key technical employees.
“We’re very pleased to complete this acquisition as it is a natural fit and extension of our successful partnership with LIVMOR and our complementary goals to dramatically improve patient outcomes and to significantly reduce healthcare system costs,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “The fact that these intellectual property and product assets were developed by the technical team that is now part of HeartBeam means that we will be able to integrate the Halo cloud-based software platform with our AIMGO solution in an efficient and cost-effective manner.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has acquired substantially all assets from LIVMOR, a digital health solutions company. Specifically, LIVMOR offers a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition allows HeartBeam to extend its reach with LIVEMOR’s FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and its physician-prescribed integrated patient-care platform. The acquisition gives HeartBeam full ownership of the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. HeartBeam and LIVMOR partnered earlier this year to build a HeartBeam-branded version of LIVMOR’s FDA-cleared, Halo, cloud-based software platform designed to connect physicians with patients. Included in the acquisition is three issued United States patents; LIVMOR technology, such as the Halo AF Detection System; LIVMOR’s business contracts and relationships; and all Samsung watch and tablet inventory; HeartBeam also hired LIVMOR’s key technical employees.
“We’re very pleased to complete this acquisition as it is a natural fit and extension of our successful partnership with LIVMOR and our complementary goals to dramatically improve patient outcomes and to significantly reduce healthcare system costs,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “The fact that these intellectual property and product assets were developed by the technical team that is now part of HeartBeam means that we will be able to integrate the Halo cloud-based software platform with our AIMGO solution in an efficient and cost-effective manner.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)